11月21日，国家卫生健康委召开新闻发布会。会上通报，当前全国流感活动已经进入较快上升期的阶 段，多数省份的流感活动水平已经到了中流行水平，个别省份达到高流行水平。 个别省份流感进入高流行水平 全国报告的托幼机构、学校流感聚集性暴发疫情的数量显著增加，5-14岁的病例组流感病毒检测阳性率 比其他年龄组显著升高。 感染流感应当尽快用药 秋冬季是呼吸道感染高发季，普通感冒和流感如何区分？怎样治疗？ 北京地坛医院主任医师宋蕊介绍，普通感冒是一种急性的上呼吸道感染性疾病，这类感染性疾病主要由 鼻病毒、副流感病毒以及呼吸道合胞病毒等相关病原体感染引起，以呼吸道局部"卡他症状"为主，包括 打喷嚏、鼻塞、流涕、咳嗽以及咽喉痛痒等症状，全身症状比较轻。感冒一般为散发病例，病程相对较 短，患者一般能在1周之内有明显缓解。 流感由流感病毒感染引起，往往来势较急，常以发烧、肌肉酸痛、全身乏力等全身症状为主且较重，但 局部"卡他症状"较轻。流感病毒有快速的检测方法，能够通过快速抗原或者核酸检测，半小时之内确 诊，确诊以后早期使用抗病毒的药物，有非常好的效果。 中国疾病预防控制中心研究员彭质斌介绍，从监测数据来看，与上一流行季是以甲型 ...

Group 1 - Sleep is essential for survival and has several important functions, including promoting growth and development, restoring energy, clearing metabolic waste, and maintaining cognitive function [2][4][5] - Sleep is crucial for immune function, as insufficient sleep can lead to increased susceptibility to illness [5] - Continuous and deep sleep is necessary for cognitive health; fragmented sleep can lead to rapid cognitive decline [8][10] Group 2 - Individuals have different sleep needs based on their unique characteristics; understanding one's own sleep requirements is important for optimal functioning [11][13] - Insomnia is a common issue, with symptoms ranging from occasional sleeplessness to chronic insomnia disorders, which can significantly impact daily functioning [12][23] - Sleep quality can be affected by various factors, including lifestyle habits, age, and underlying health conditions [16][19][22] Group 3 - Sleep duration and quality are linked to overall health; both excessive and insufficient sleep can increase mortality risk and other health issues [19][18] - The importance of maintaining a regular sleep schedule and healthy lifestyle habits, including diet and exercise, is emphasized for better sleep quality [53][54] - Various methods, such as cognitive behavioral therapy for insomnia (CBTI), can be effective in treating sleep disorders [44][45]

Core Insights - Sleep disorders have become a significant health issue affecting nearly half of the adult population in China, with a sleep disturbance rate of 48.5% among individuals aged 18 and above [1][2] - The average sleep duration for this demographic is between 7.06 to 7.18 hours, with women experiencing higher rates of sleep disturbances (51.1%) compared to men (45.9%) [1] - The prevalence of sleep disturbances increases with age, peaking at 73.7% among those aged 65 and above [1] Group 1: Health Implications - Insomnia is linked to various physical and mental health issues, including hypertension, diabetes, coronary heart disease, and cancer [1] - It also contributes to increased anxiety and a higher risk of suicide, as well as a rise in traffic accidents and decreased work efficiency, leading to greater socioeconomic burdens [1][2] Group 2: Treatment and Interventions - Multiple intervention methods for insomnia include lifestyle adjustments, psychological therapy, and pharmacological treatments, with a focus on cognitive behavioral therapy (CBT-I) as a primary approach [3][4] - New drug developments, particularly DORA (Dual Orexin Receptor Antagonists), aim to improve sleep quality without the side effects associated with traditional insomnia medications [5][6] Group 3: Market Potential - The sleep economy in China is projected to reach a market size of 534.93 billion yuan in 2024, with expectations to grow to 658.68 billion yuan by 2027, indicating strong growth potential [4] - The insomnia medication market was valued at 12.28 billion yuan in 2021, with forecasts of reaching 15.12 billion yuan by 2025 and 21.19 billion yuan by 2030 [5] Group 4: Regulatory and Accessibility Aspects - Recently approved DORA medications, such as Lemborexant and Daridorexant, have been included in the preliminary review list for the national medical insurance directory, enhancing their market accessibility [6] - These medications are not classified as controlled substances, which increases patient access and allows for innovative distribution channels, including e-commerce [6][7]

为了进一步探究达利雷生的药物价值，先声药业神经与肿瘤药物研发全国重点实验室主任唐任宏博士介 绍，随着达利雷生的上市，公司计划每年投入1000万元，三年总共3000万元的投入，帮助更好地研究达 利雷生对患者的价值。具体的开放课题则包括：亚组研究，比如达利雷生用于失眠合并焦虑/抑郁患 者、失眠合并AD/PD患者的有效性和安全性研究；特殊人群，比如达利雷生用于失眠合并肿瘤患者、心 血管疾病患者、风湿免疫病患者、OSA患者、卒中患者的有效性和安全性研究；达利雷生与其他失眠药 物桥接切换的真实世界研究；达利雷生真实世界长期应用研究等。 （文章来源：证券日报） 近年来，如何睡得好成为老百姓普遍关心的问题。根据中国睡眠研究会《2025年中国睡眠健康调查报 告》，中国18岁及以上人群睡眠困扰率为48.5%，主要症状表现为入睡困难、夜间易醒、早醒等。北京 大学第六医院院长岳伟华教授表示，如果患者失眠症状每周出现3次以上，持续3个月以上，建议及时前 往医院睡眠、精神、心理、神经等相关科室就诊。具体失眠症状包括：入睡困难，卧床超过30分钟仍无 法入睡；睡着后觉醒2次以上且难再入睡；清晨早醒30分钟以上；白天嗜睡、记忆功能下降、焦虑 ...

8月初，新型抗失眠药物莱博雷生（商品名：达卫可）在电商平台首发，第一天就售出8000多盒。谈及这个数字，卫材中国总裁冯艳辉直呼"没想到"。 "原先我们只注意到医院市场。"就在莱博雷生上市前夕，一位院长还向她表达了对该产品的期待，因为医院过去十多年都只有老药可用。 自2007年之后，国内失眠治疗领域一度长达十多年没有创新药上市，2023年上市的一款药物，虽然在作用机制上有所创新，但仍属于传统的苯二氮䓬类受体 激动剂，同类药物使用历史已超过半个世纪。今年5月底获批的莱博雷生，作为首个在中国上市的双食欲素受体拮抗剂，真正属于全新靶点的创新药，可谓 给国内失眠治疗带来一场革新。2024年，莱博雷生全球销售额为3.7亿美元，居同类产品之首。 冯艳辉总裁提到，虽然莱博雷生在已上市的20多个国家及地区均获得较好的市场反响，特别是在失眠大国日本，莱博雷生在助眠药物处方市场的份额已达到 40%。但在中国上市后的成绩仍出乎卫材团队的意料之外，他们没想到在医院市场之外，莱博雷生的产品需求竟也如此旺盛。 因为属于非镇静类药物，对睡眠结构的调节（通过抑制食欲素的促觉醒作用，诱导睡眠）更趋近生理自然状态，以及较少的副作用，莱博雷生并未被 ...

Core Insights - The launch of the new insomnia drug, Lemborexant (brand name: Dazai Ke), on e-commerce platforms in early August saw over 8,000 boxes sold on the first day, surprising the company [1] - Lemborexant is the first dual orexin receptor antagonist approved in China, marking a significant innovation in the insomnia treatment market after a decade without new drugs [1][2] - The drug has achieved a global sales forecast of $370 million in 2024, leading its category [1] - The drug's success in China was unexpected, as the company initially focused on the hospital market, but demand from e-commerce channels proved strong [1] Market Potential - There are hundreds of millions of people in China suffering from sleep disorders, indicating a vast potential market for insomnia treatments [2] - Lemborexant is not classified as a controlled substance, allowing easier access for patients compared to traditional sedative medications [2] Patient Experience - A patient named Li Wei, who has struggled with insomnia for years, reported positive experiences with Lemborexant, noting improved sleep quality without significant side effects [9] - However, not all patients have had the same success, with some experiencing difficulties in adjusting to the new medication [9] Treatment Guidelines - The treatment of insomnia requires a tailored approach, considering various underlying conditions and the need for proper medication management [10] - The company emphasizes the importance of rational drug use and gradual transitions from traditional medications to Lemborexant to avoid withdrawal symptoms [10][12] Healthcare System Challenges - There is a lack of specialized clinics for sleep disorders in China, making it difficult for patients to receive appropriate care [14] - The government is promoting the establishment of sleep clinics, with a goal for widespread availability by 2027, but challenges remain in integrating multidisciplinary approaches [14] Future Directions - The company plans to focus on sleep health management, aiming to expand market access for Lemborexant and develop new drugs targeting other sleep-related issues [15] - Collaboration with healthcare providers and institutions is encouraged to enhance clinical experience and public awareness regarding sleep health [15]